Eye institute and Dainippon to develop iPS cell-based therapies

04/1/2013 | Genetic Engineering & Biotechnology News

Retina Institute Japan will receive about $16 million in an investment from Dainippon Sumitomo Pharma as part of a deal to work on new induced pluripotent stem cell-based therapies. The investment will give Dainippon a 5% stake in the institute. The partnership's focus will include treatments for refractory retinal disease and age-related macular degeneration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ